Blockchain Registration Transaction Record

Alpha Cognition's ZUNVEYL Shows 102% Growth in LTC Channel

Alpha Cognition reports 102% growth in ZUNVEYL pharmacy orders, expanding to 600+ nursing homes. Q3 revenue hits $2.8M with patent protection extended to 2044.

This development matters because Alzheimer's disease and related cognitive disorders affect millions of patients and their families worldwide, creating an urgent need for effective treatments. Alpha Cognition's accelerating commercial success with ZUNVEYL demonstrates real-world adoption and physician confidence in a therapeutic area where treatment options remain limited. The company's expansion into more than 600 nursing homes and growing prescriber base indicates that healthcare providers are finding value in this medication for their patients. Furthermore, the research pipeline advancements, particularly the promising results in traumatic brain injury and development of alternative formulations for patients with swallowing difficulties, suggest broader potential applications beyond Alzheimer's disease. For investors, the combination of strong commercial momentum, extended patent protection to 2044, and substantial financial runway positions Alpha Cognition as a company worth watching in the neurodegenerative disease treatment space.